Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors. The ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Monday. So, we’ve got a welcome bump in the XBI, see that European ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

BioTech ETFs (exchange-traded funds) offer investors exposure to the biotechnology sector. This sector is known for medical breakthroughs and technological advances and hence has the potential for ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at biotech’s latest nadir, the ...

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market. Products that are based on market cap ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. The ETF industry has ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...